Clinical Trials Directory

Trials / Unknown

UnknownNCT04012801

Evaluation of C13 Breath Test for Upper Gastrointestinal Bleeding in Patients Who Need Double Antiplatelet After PCI

Evaluation of C13 Breath Test for Upper Gastrointestinal Bleeding in Patients of Acute Myocardial Infarction Who Need Double Antiplatelet After PCI

Status
Unknown
Phase
Study type
Observational
Enrollment
1,500 (estimated)
Sponsor
Chongqing Medical University · Academic / Other
Sex
All
Age
24 Years – 93 Years
Healthy volunteers
Not accepted

Summary

Hp infection is closely related to upper gastrointestinal bleeding in patients who need dual-antiplatelet after PCI. Taking anti-Hp treatment has the effect of reducing bleeding risk. Thus, we propose a scientific hypothesis: the C13 breath test may be used to assess the risk of upper gastrointestinal bleeding in patients who need dual- antiplatelet after PCI.

Detailed description

Our study is to retrospectively analyze the clinical data of 1606 patients of acute myocardial infarction who need dual- antiplatelet after PCI.The diagnostic criteria for upper gastrointestinal bleeding is: 1.symptoms: digestive discomfort, such as abdominal pain, nausea, belching, acid reflux, etc.;2.mainly based on endoscopy examination, endoscopic examination showed that the stomach or duodenum showed spotted, linear or diffuse bleeding;3.the fecal examination:melena, tar-like stool, hematemesis, fecal occult blood, etc.The study was divided into two groups according to whether the C13 breath test was performed, and the C13 breath test component was the positive anti-HP treatment group and the non-anti-HP treatment group.And then compare the upper gastrointestinal bleeding rates of the above groups.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTC13 breath testC13 breath test for patients of acute myocardial infarction who need dual- antiplatelet after PCI.

Timeline

Start date
2015-01-01
Primary completion
2020-07-01
Completion
2020-07-01
First posted
2019-07-09
Last updated
2020-03-04

Source: ClinicalTrials.gov record NCT04012801. Inclusion in this directory is not an endorsement.